RxDoctor Payments Data

Thomas Fitzgerald, MD

Radiation Oncology · Worcester, MANPI 1982688214

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. That places this record below the midpoint for radiation oncology clinicians in MA, where the typical reported total is $145.

$66in general payments, 2019–2025

Across 3 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mevion_medical_systems_inc$36
  • Palette Life Sciences, Inc.$30
$729,638in research payments, 2019–2025

Across 8 payments — averaging $91,205 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$441K
  • Merck$289K

What the payments were for

  • Food & beverage$66100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mevion_medical_systems_inc2$36
Palette Life Sciences, Inc.1$30

How this compares

$66 in reported general payments places this provider in the 35th percentile of 200 radiation oncology providers in Massachusetts.

See all radiation oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$311,201
Medicare patients
285
Services billed
3,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl24$366

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →